文献速递胸部肿瘤放疗放疗物理与技术

常规分割放疗联合免疫治疗后的肺炎:一种剂量学评估方法

Pneumonitis after normofractionated radioimmunotherapy: a method for dosimetric evaluation.
PubMed 文献 · Radiat Oncol · 2024-11-22

本研究开发了一种方法,用于评估胸部放疗联合或不联合免疫检查点抑制剂后发生治疗后肺炎(PTP)的剂量学参数变化;

要点

  • 方法可将随访CT上的PTP体积形变配准至计划CT并进行EQD2剂量学分析。
  • R(C)T+ICI组与单纯R(C)T组PTP剂量学参数无显著差异。
  • R(C)T+ICI组55%的PTP体积位于EQD2<40 Gy区域。

核心结论

  • 所提出的方法能够量化R(C)T+ICI与单纯R(C)T患者PTP剂量体积效应关系的剂量学差异。
  • 在此探索性分析中,不同组间PTP体积内未观察到显著剂量学差异。
  • 作者认为,为安全应用胸部R(C)T+ICI,建议进一步仔细研究剂量学处方与分析概念,并采用更大且更一致的研究组。

研究设计与样本

  • 方法学研究,在内部患者队列中示例性测试,该队列包括90例接受胸部R(C)T+ICI(39例)和R(C)T(51例)的患者。
  • PTP体积在随访诊断CT上勾画并形变配准至计划CT,剂量数据转换为2 Gy等效剂量(EQD2)后进行剂量学分析。

主要发现

  • R(C)T+ICI组与单纯R(C)T组之间未观察到显著差异。
  • R(C)T+ICI组PTP体积中55%位于高剂量(EQD2<40 Gy)区域之外。
  • R(C)T+ICI组剂量体积直方图曲线下面积(AUC)较单纯R(C)T组呈非显著升高趋势(3743.6 Gy∙% vs. 2848.8 Gy∙%;p值=0.171)。
  • 与姑息性治疗组数据相反,根治性R(C)T+ICI组数据倾向于更高剂量下体积增加。

关键数值与推荐

  • R(C)T+ICI组AUC为3743.6 Gy∙%,单纯R(C)T组为2848.8 Gy∙%(p值=0.171)。
  • R(C)T+ICI组PTP体积中55%位于EQD2<40 Gy区域之外。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为,为安全应用胸部R(C)T+ICI,建议进一步仔细研究剂量学处方与分析概念,并采用更大且更一致的研究组。
  • 此分析为探索性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Post-Therapy-Pneumonitis (PTP) is a critical side effect of both, thoracic radio(chemo)therapy (R(C)T) and immune checkpoint inhibition (ICI). However, disease characteristics and patient-specific risk factors of PTP after combined R(C)T + ICI are less understood. Given that RT-triggered PTP is strongly dependent on the volume and dose of RT [1], driven by inflammatory mechanisms, we hypothesize that combination therapy of R(C)T with ICI influences the dose-volume-effect correlation for PTP. This study focuses on the development of a method for evaluation of alterations of dosimetric parameters for PTP after R(C)T with and without ICI. METHODS AND MATERIALS: PTP volumes were delineated on the follow-up diagnostic Computed Tomography (CT) and deformably matched to the planning CT for patients with PTP after thoracic R(C)T + ICI or R(C)T. Dose data was converted to 2-Gy equivalent doses (EQD2) and dosimetrically analyzed. Dosimetric and volumetric parameters of the segmented PTP volumes were analyzed. The method was exemplarily tested on an internal patient cohort including 90 patients having received thoracic R(C)T + ICI (39) and R(C)T (51). Thirtytwo patients with PTP were identified for further analysis. Additional data on previous chemotherapy, RT, smoking status and pulmonary co-morbidity were conducted. A matched pair analysis with regard to planning target volumes (PTV) was conducted for curative intended (definitive) and palliative patient cohorts individually. RESULTS: The presented method was able to quantify and compare the dosimetric parameters of PTP for the different therapies. For our study group, no significant differences between R(C)T + ICI and R(C)T only was observed. However, the dosimetric analysis revealed large volumetric fractions (55%) of the PTP volumes to be located outside of high dose (EQD2 < 40 Gy) regions for R(C)T + ICI. There was a non-significant trend towards increased area under the curve of the dose volume histogram (AUC) values for R(C)T + ICI compared to R(C)T only (3743.6 Gy∙% vs. 2848.8 Gy∙%; p-value = 0.171). In contrast to the data for the palliative intended treatment group, for definitive R(C)T + ICI, data tended towards increased volumes with higher doses. CONCLUSIONS: The proposed method was capable to quantify dosimetric differences in the dose-volume-effect relationship of PTP for patients with R(C)T + ICI and patients with R(C)T only. In this exploratory analysis, no significant dosimetric differences within PTP volumes for the different groups could be observed. However, our observations suggest, that for safe application of thoracic R(C)T + ICI, further careful investigation of dosimetric prescription and analysis concepts with larger and conformer study groups is recommendable.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kraus KM, Bauer C, Steinhelfer L, et al. Pneumonitis after normofractionated radioimmunotherapy: a method for dosimetric evaluation. Radiat Oncol. 2024. PMID: 39574136. doi:10.1186/s13014-024-02561-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。